Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Paul C. Nathan
{"title":"儿童脑外胶质瘤患者的医疗和功能负担:加拿大安大略省的一项人口研究。","authors":"Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Paul C. Nathan","doi":"10.1002/pbc.31275","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real-world health services data in a population-based ependymoma survivor cohort.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post-index, survivors were at significantly higher risk of all-cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; <i>p</i> = .0002), non-obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; <i>p</i> < .0001), stroke (6.5%, 95% CI: 2.3–13.7 vs. 0%; <i>p</i> < .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7–15.7 vs. 0%; <i>p</i> < .0001), receiving homecare service (27.6%, 95% CI: 18.5–37.5 vs. 7.7%, 95% CI: 5.3–10.7; <i>p</i> < .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8–34.3 vs. 5.4%, 95% CI: 3.5–7.8; <i>p</i> < .0001) compared to controls.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk-stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long-term health.</p>\n </section>\n </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31275","citationCount":"0","resultStr":"{\"title\":\"The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada\",\"authors\":\"Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Vijay Ramaswamy, Paul C. Nathan\",\"doi\":\"10.1002/pbc.31275\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real-world health services data in a population-based ependymoma survivor cohort.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post-index, survivors were at significantly higher risk of all-cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; <i>p</i> = .0002), non-obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; <i>p</i> < .0001), stroke (6.5%, 95% CI: 2.3–13.7 vs. 0%; <i>p</i> < .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7–15.7 vs. 0%; <i>p</i> < .0001), receiving homecare service (27.6%, 95% CI: 18.5–37.5 vs. 7.7%, 95% CI: 5.3–10.7; <i>p</i> < .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8–34.3 vs. 5.4%, 95% CI: 3.5–7.8; <i>p</i> < .0001) compared to controls.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk-stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long-term health.</p>\\n </section>\\n </div>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31275\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31275\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31275","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada
Background
Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real-world health services data in a population-based ependymoma survivor cohort.
Methods
All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.
Results
Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post-index, survivors were at significantly higher risk of all-cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; p = .0002), non-obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; p < .0001), stroke (6.5%, 95% CI: 2.3–13.7 vs. 0%; p < .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7–15.7 vs. 0%; p < .0001), receiving homecare service (27.6%, 95% CI: 18.5–37.5 vs. 7.7%, 95% CI: 5.3–10.7; p < .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8–34.3 vs. 5.4%, 95% CI: 3.5–7.8; p < .0001) compared to controls.
Conclusions
Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk-stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long-term health.
期刊介绍:
Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.